Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Akums Drugs Q4 profit declines, but EBITDA jumps 62%; declares special dividend
Akums Drugs reported a mixed set of fourth-quarter earnings, with profit declining sharply despite healthy revenue growth and strong margin expansion, while the board announced a final and special dividend.
Caplin Point shares surge over 9% after Q4 results — Profit up 19%; dividend declared
Caplin Point’s board also approved an interim dividend of ₹4 per equity share for FY26. The company has fixed May 30, 2026, as the record date for determining shareholder eligibility for the dividend.
Nifty above 23,500 level; pharma shares in demand
At 10:30 IST, the barometer index, the S&P BSE Sensex, advanced 228.50 points or 0.31% to 74,837.48. The Nifty 50 index rose 98.85 points or 0.42% to 23,511.40.
Metropolis Healthcare Q4 profit zooms 2x on higher revenue, margins; declares dividend
Revenue on a consolidated basis rose 23% year-on-year to ₹425 crore from ₹345 crore. EBITDA increased 73.4% to ₹108 crore, while margins improved to 25.4% from 18% a year ago. Shares of Metropolis Healthcare Ltd ended at ₹550, up by ₹2, or 0.36%, on the BSE today, May 13.
Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividend
Cipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also declined. Despite these figures, key therapies and trade generics business showed strong growth. The company plans to focus on expanding its markets and developing its future pipeline. A final dividend of Rs 13 per equity share has been recommended.
Cipla Q4FY26 Results: Net Profit Down 54.6%, Dividend Announced — Check Record Date
Cipla's board recommended a final dividend of Rs 13 per share for FY26, payable within 30 days post-AGM, with June 5, 2026, as the record date for dividend payment.
Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividend
Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This contrasts with Rs 1,222 crore reported in the same period last year. The company's Board has recommended a final dividend of Rs 13 per share for the fiscal year ending March 2026.
Cipla Q4 Results: An All-Around Miss As Profit Tanks 54%
Apart from its Q4 earnings, Cipla also announced a final dividend of Rs 13 per share.
Cipla Q4 Results: Net profit falls 55% to ₹554.64 crore, revenue drops 3% YoY; declares dividend of ₹13 per share
Cipla Q4 Results: The company’s revenue from operations in Q4FY26 declined 2.80% to ₹6,541.20 crore from ₹6,729.69 crore, year-on-year (YoY)
Pfizer Q4 profit falls despite revenue, EBITDA growth; ₹75 dividend declared
Pfizer reported a decline in fourth-quarter profit despite higher revenue and EBIDTA, while the board recommended a final dividend of ₹75 per share for FY26.
Pfizer Declares Bumper Dividend Of Rs 75/Share Even As Q4 Profit Slides; Check Record Date
Notably, the pharma giant's net profit for the fourth quarter of FY26 has slumped 39.6% year-on-year to Rs 200 crore
Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced
Dr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter versus Rs 1,587 crore in the year ago period, an 86% YoY fall.